Description
Goustat 40 mg is an oral medication manufactured by ACME Laboratories Ltd., containing Febuxostat, a non-purine selective xanthine oxidase inhibitor. It is primarily used for the chronic management of hyperuricemia in patients with gout, a condition characterized by elevated uric acid levels leading to joint inflammation and pain. Febuxostat works by inhibiting xanthine oxidase, an enzyme responsible for converting purines into uric acid, thereby reducing serum uric acid levels. This mechanism helps prevent gout attacks and complications associated with chronic hyperuricemia. The recommended starting dose is 40 mg once daily, which may be increased to 80 mg daily if target uric acid levels are not achieved after two weeks. Goustat should be taken as prescribed by a healthcare professional, and patients are advised to monitor for potential side effects such as liver function abnormalities, gout flares, and gastrointestinal symptoms. It is important to note that Goustat is contraindicated in patients receiving concomitant therapy with azathioprine, mercaptopurine, or theophylline due to potential drug interactions.
.jpeg)
.png)
.webp)
.webp)
.jpeg)
.png)
.jpeg)
.webp)
.png)
Change Language